Search Results
Your search for ,New matches 16912 pages
Showing 11101 - 11150Patient-Reported Outcomes After Active Monitoring, Surgery, or Radiotherapy in PSA-Detected Localized Prostate Cancer
Patient-reported outcomes differed among men with localized prostate cancer detected by prostate-specific antigen (PSA) testing who were randomized to receive active monitoring, surgery, or radiotherapy in the UK ProtecT trial, according to a report by Donovan et al in The New England Journal of...
ASCO/ASTRO/SSO Develop Focused Guideline Update on Postmastectomy Radiotherapy
As reported by Recht et al in the Journal of Clinical Oncology, a joint ASCO, American Society for Radiation Oncology (ASTRO), and Society of Surgical Oncology (SSO) panel has developed a focused guideline update of the ASCO guideline on postmastectomy radiotherapy. A recent Cancer Care Ontario...
ASTRO 2016: Unmet Need for Radiation Therapy Found Among Nearly Half of Eligible Cancer Patients in Nine Developing Countries
Although approximately 50% of cancer patients in developing countries need radiation therapy to treat their disease, up to half of these patients do not have access to it, according to research presented by Rosenblatt et al at the 58th Annual Meeting of the American Society for Radiation Oncology...
Ratio of Certain Immune Cells in the Blood to Tumor Burden Correlated With Outcome for Melanoma Patients Treated With Pembrolizumab
Although some patients with melanoma experience durable responses to treatment with the anti–PD-1 (programmed cell death protein 1) therapy pembrolizumab (Keytruda), the majority of patients do not experience a durable clinical benefit from anti–PD-1 monotherapy, according to a study by ...
Richard T. Hoppe, MD, on Lymphoma: Improving Outcomes
Richard T. Hoppe, MD, of Stanford University, summarizes a session on improving outcomes by enhancing old and new indications in follicular lymphoma and Hodgkin lymphoma. (Scientific Session 5)
Louis Harrison, MD, on Radiation Oncology and the Future of Health Care
Louis B. Harrison, MD, of the Moffitt Cancer Center, discusses radiation oncology in the context of personalized medicine, multidisciplinary care, new technology and applications, and the mandate to contain costs.
Combining AM0010 and Pembrolizumab Produced Antitumor Activity in Patients With Advanced Solid Tumors
A multibasket phase Ib study evaluating the clinical activity, tolerability, and antitumor activity of the cytokine-based immunotherapy AM0010 alone or in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) has found that in monotherapy, objective responses to AM0010 were ...
Improved Event-Free Survival With Addition of Rituximab to Chemotherapy in B-Lineage Adult ALL
In the phase III GRAALL-2005 trial reported in The New England Journal of Medicine, Maury et al found that the addition of rituximab (Rituxan) to standard chemotherapy resulted in improved event-free survival in adult patients with B-lineage acute lymphoblastic leukemia (ALL). Study Details In...
Addition of CHK1 Inhibitor Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy
Combining a new targeted drug that blocks one of cancer’s escape routes could boost the effectiveness of combined chemoradiotherapy for head and neck cancers and stop cells becoming resistant to treatment. Researchers at The Institute of Cancer Research, London (ICR), and The Royal Marsden...
Blood Biomarkers in Abiraterone- or Enzalutamide-Resistant Prostate Cancer Tumor Cells
While searching for a noninvasive way to detect prostate cancer cells circulating in blood, Duke Cancer Institute researchers have identified some blood markers associated with tumor resistance to two common hormone therapies. In a study published by Gupta et al in Clinical Cancer Research, a team...
Large Study Finds No Link Between Vasectomy and Prostate Cancer Risk
In a new study, men who underwent vasectomy did not have an increased risk of prostate cancer, nor were they more likely to die from prostate cancer than men who did not receive this procedure. According to the researchers, this is the largest prospective study of vasectomy and fatal prostate...
Saul J. Sharkis, PhD, Stem Cell Researcher, Dies
Saul J. Sharkis, PhD, a scientist who studied the biology of blood stem cells and how they could be used to treat cancer through bone marrow transplantation, died on September 4. He was 72. Dr. Sharkis was Professor of Oncology at the Johns Hopkins University School of Medicine and a faculty...
Study Confirms Benefit of Cobimetinib Plus Vemurafenib in Advanced BRAF V600–Mutant Melanoma
As reported by Ascierto et al in The Lancet Oncology, longer-term follow-up in the pivotal phase III coBRIM trial confirmed the benefit of adding cobimetinib to vemurafenib (Zelboraf) in first-line treatment of BRAF V600–mutant unresectable stage IIIC or IV melanoma. Grant A. McArthur, FRACP, of...
Olanzapine Combination Reduces Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
According to a phase III trial reported by Navari et al in The New England Journal of Medicine, the addition of the antipsychotic agent olanzapine vs placebo to dexamethasone, aprepitant, or fosaprepitant, and a 5-hydroxytryptamine type 3–receptor antagonist reduced nausea and improved antiemetic...
Updated Outcomes, Impact of Age in Multiple Myeloma
Updated Outcomes, Impact of Age in Multiple Myeloma As reported by Hulin et al in the Journal of Clinical Oncology, the updated findings in the phase III FIRST trial continue to show improved progression-free and overall survival with continuous lenalidomide (Revlimid) plus low-dose dexamethasone...
2016-2017 Oncology Meetings
OCTOBER International Cancer Imaging Society Meeting and 16th Annual Teaching CourseOctober 3-5 • Glasgow, ScotlandFor more information:http://www.icimagingsociety.org.uk/index.cfm?task=meetings 9th International Workshop on Waldenstrom’s Macroglobulinemia & Symposia on Multiple MyelomaOctober...
Michael Maitland, MD, PhD, Named Director of Therapeutics for the Inova Center for Personalized Health
Inova Health System is pleased to welcome Michael Maitland, MD, PhD, where he will serve as the new Director of Therapeutics for the Inova Center for Personalized Health and as Associate Director of Cancer Therapeutics for the Inova Schar Cancer Institute. Dr. Maitland comes to Inova from the...
Cancer Moonshot Blue Ribbon Panel Recommends 10 Ways to Speed Cancer Advances
Earlier this month, members of the National Cancer Moonshot Initiative’s Blue Ribbon Panel submitted an ambitious list of 10 recommendations on the scientific approaches that are most likely to accelerate progress against cancer to the President’s National Cancer Advisory Board. The panel’s...
2016 Lasker Awards Honor Scientists for Basic and Clinical Medical Research, Special Achievement
The Albert and Mary Lasker Foundation has announced the winners of the 2016 Lasker Awards for medical science: William G. Kaelin, MD; Peter J. Ratcliffe, MD, FRCP, FMedSci, FRS; and Gregg L. Semenza, MD, PhD for basic medical research; Ralf F.W. Bartenschlager, PhD; Charles M. Rice, PhD;...
The Halifax Project: A New Approach to Combination Therapy
On August 13, 2013, more than 100 cancer researchers and physicians from around the world met in Halifax, Nova Scotia, Canada, to discuss 2 challenging problem areas in cancer. One group was focused on the carcinogenic potential of low-dose exposure to chemical mixtures in the environment, and the...
Pioneer in Chemoradiation Robert B. Livingston, MD, Dies
Over the past couple of decades, chemoradiation for several cancers, such as lung and breast, has advanced in efficacy and side-effect tolerance, prolonging survival and quality of life for patients. One of the pioneers in chemoradiation, Robert B. Livingston, MD, died on September 8, 2016. Dr....
Recognizing the Unique Experiences of Cancer Among Adolescent and Young Adult Survivors
Studies show that adolescent and young adult cancer survivors experience distinct challenges and quality-of-life issues from those experienced by either younger or older adult cancer survivors and that those challenges and issues can persist long after the cancer diagnosis and the end of...
FDA Approves Blinatumomab for Use in Pediatric Patients With Ph-Negative Relapsed or Refractory B-Cell Precursor ALL
The U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for blinatumomab (Blincyto) to include new data supporting the treatment of pediatric patients with Philadelphia chromosome (Ph)-negative relapsed or refractory B-cell precursor acute...
Bassel El-Rayes, MD, to Hold John Kauffman Family Professorship at Winship
Bassel F. El-Rayes, MD, Associate Director of Clinical Research at Winship Cancer Institute of Emory University, was selected to hold the John Kauffman Family Professorship for Pancreatic Cancer Research. The new position was created to support an outstanding leader in the field of pancreatic...
Researcher Spotlight: Conquering Cancer With Dr. Effinger
When it comes to pediatric cancer, there are so many signs of hope, starting with the fact that the childhood cancer 5-year survival rate has climbed all the way up to 83%. But while we celebrate the victories of all these children over cancer, little is known about the long-term health effects,...
Cancer Survivorship Symposium Brings Together Oncologists and Primary Care Providers to Improve Patient Care
Significant advances in cancer care and treatment have led to a steady increase in survivorship—currently, more than 15.5 million cancer survivors are living in the United States. This number is only expected to grow, with an estimate of more than 20 million American cancer survivors in 2026.1 A...
ASCO Continues Active Involvement in Cancer Moonshot
This summer, ASCO continued its active involvement in Vice President Joe Biden’s Cancer Moonshot Initiative. ASCO joined the Vice President at the formal launch of the moonshot earlier this year, and since then, has discussed research and policy proposals to advance discovery in cancer treatment...
Breaking the ‘Conspiracy of Silence’
A new study1 showing that just 1 in 20 terminally ill patients with cancer has sufficient understanding about the prognosis or purpose of treatment is highlighting the need for improvements in both the way oncologists communicate prognosis with their patients and in the development of educational...
The Role of Music Therapy in Cancer Care
Music therapy, an established adjuvant to standard cancer care, is offered in a growing number of cancer centers throughout the United States and internationally. Defined by the American Music Therapy Association (AMTA) as “the evidence-based use of music interventions to accomplish individual...
Improving Management of Sexual Problems for Cancer Survivors
What do up to 60% of cancer survivors have in common? Answer: some type of long-term sexual dysfunction. How many cancer survivors seek professional help for sexual problems? Answer: less than 20%. Even when they do seek help, they may not be successful in finding professionals with expertise in...
Why Patients’ Understanding of Their Prognosis Often Differs From Their Oncologists’
A recent study1 published in the Journal of Clinical Oncology (see “Breaking the ‘Conspiracy of Silence’” in this issue of The ASCO Post) found that just 1 in 20 patients with advanced, incurable cancer has sufficient understanding of his or her prognosis or life expectancy. Now, another new study ...
FDA Takes Action Against 55 Tobacco Retailers for Selling Newly Regulated Products to Minors
The U.S. Food and Drug Administration (FDA) announced on September 15 that it has taken action against 55 tobacco retailers by issuing the first warning letters for selling newly regulated tobacco products—such as e-cigarettes, e-liquids, and cigars—to minors. These actions come about a month after ...
I-SPY 2: Separating Contenders From Pretenders in Breast Cancer
With the expansion of our understanding of signaling pathways in normal cells and how they are co-opted or corrupted in malignancy, the number of potential antitumor agents to be tested has exploded, exposing the limitations of traditional antineoplastic drug development and challenging us to...
Nonwhite Organ Transplant Recipients Also at Heightened Risk for Skin Cancer
A new study from Drexel University College of Medicine suggests all organ transplant recipients, regardless of race, should receive routine, total-body screenings for skin cancer. Out of 259 nonwhite transplant recipients who were evaluated in the study, 19 skin cancer lesions were identified in...
High-Calcium, Low-Lactose Diet May Reduce Risk of Ovarian Cancer in African American Women
Research from Rutgers Cancer Institute of New Jersey and and other U.S. health and academic institutions shows a diet high in calcium and low in lactose may reduce the risk of ovarian cancer in African American women. The work, published by Qin et al in the British Journal of Cancer, also found sun ...
Survival Benefit Reported With Maintenance Olaparib in Platinum-Sensitive Recurrent Serous Ovarian Cancer With BRCA Mutation
Maintenance olaparib (Lynparza) appeared to be associated with an overall survival benefit vs placebo in women with platinum-sensitive serous ovarian cancer and BRCA1 and BRCA2 mutations, according to an updated analysis of a phase II trial reported in The Lancet Oncology by Ledermann et al....
Neoadjuvant Veliparib/Carboplatin and Neratinib ‘Graduate’ From Adaptive Randomization I-SPY 2 Trial in Early Breast Cancer
As reported by Hope S. Rugo, MD, and John W. Park, MD, both of the University of California, San Francisco, and colleagues in The New England Journal of Medicine, the multiarm adaptive randomization phase II I-SPY 2 trial has shown that the addition of veliparib/carboplatin and the addition of...
Maha H. Hussain, MD, Joins the Lurie Cancer Center
Maha H. Hussain, MD, has joined the Robert H. Lurie Comprehensive Cancer Center of Northwestern University as the Associate Director for Clinical Sciences Research. Dr. Hussain will also serve as Co-Director of the Lurie Cancer Center’s Genitourinary Oncology Program, along with Edward Schaeffer,...
Julie E. Bauman, MD, MPH, Named Chief of Hematology/Oncology, Associate Director of Translational Research at UA Cancer Center
Julie E. Bauman, MD, MPH, a head and neck cancer specialist and physician-scientist, has been named Professor of Medicine and the new Chief of the Division of Hematology and Oncology at the University of Arizona (UA) College of Medicine–Tucson, as well as Associate Director of Translational...
4th Annual Basser Global Prize Awarded to Women’s Cancer Geneticist Steven Narod, MD, FRCPC, PhD (hon), FRSC
The Basser Center for BRCA at Penn’s Abramson Cancer Center has announced the recipient of the 2016 Basser Global Prize is cancer geneticist Steven Narod, MD, FRCPC, PhD (hon), FRSC, Director of the Familial Breast Cancer Research Unit and a senior scientist at the Women’s College Hospital in...
FDA Grants Priority Review to Pembrolizumab Supplemental Biologics License Application for First-Line Treatment of Advanced NSCLC
The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda), an anti–PD-1 (programmed cell death protein 1) therapy, for the first-line treatment of patients with advanced non–small cell lung cancer...
Lung Cancer Specialist Shares Clinical Pearls for Managing Stage IIIA Non–Small Cell Lung Cancer
Clinicians face a number of questions in evaluating and treating patients with stage IIIA non–small cell lung cancer (NSCLC). One expert in the field, Rafael Santana-Davila, MD, reviewed key issues in managing this disease in the Journal of Oncology Practice (JOP). The ASCO Post asked Dr....
Updated USPSTF Guidelines for Colorectal Cancer Screening: More Methods, More Challenges for Patients and Providers Alike
As reviewed in this issue of The ASCO Post, the U.S. Preventive Services Task Force (USPSTF) recently updated its guidelines for colorectal cancer screening1 from 2008 and has now included seven acceptable strategies, including direct-visualization modalities (ie, endoscopy and computed tomography...
New USPSTF Recommendations for Colorectal Cancer Screening
As reported in JAMA, the U.S. Preventive Services Task Force (USPSTF) has issued new recommendations for colorectal cancer screening.1 In brief, the USPSTF recommends colorectal cancer screening starting at age 50 years and continuing until age 75 years (grade A recommendation = “The USPSTF...
FDA Approves Ofatumumab in Combination With Fludarabine and Cyclophosphamide for Relapsed CLL
The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for the use of ofatumumab (Arzerra) in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL). The application, which...
ASH Presents Charles Mullighan, MBBS (Hons), MD, With the 2016 William Dameshek Prize
The American Society of Hematology (ASH) will present the 2016 William Dameshek Prize to Charles Mullighan, MBBS (Hons), MD, of St. Jude Children’s Research Hospital, for his leadership in defining the landscape of genetic alterations of acute lymphocytic leukemia (ALL), which has provided...
Novel Agents on the Horizon in Lymphoma
Attendees at the 2016 Pan Pacific Lymphoma Conference held July 18–22 in Koloa, Hawaii, got a peek at early data for a number of novel agents in the treatment of various lymphoma subtypes. The ASCO Post captured these findings. Denintuzumab Mafodotin in Diffuse Large B-Cell Lymphoma Denintuzumab...
Expert Point of View: Benjamin L. Judson, MD
“This (adverse cardiac effects of chemotherapy) is a difficult problem to address because the side effects of chemotherapy in terms of its impact on the heart show up many years, sometimes decades, later. So that makes it harder to study and treat. It’s a real problem,” commented session...
Reducing Drug Costs by Increasing Science-Driven Drug Discovery
For several years now, the American health-care system has been undergoing a transformation. Innovative ideas are being explored, new systems continue to be created, and millions of lives have been impacted. As health-care providers and research engines, academic institutions have an opportunity...
ASCO and AACI Initiative to Reduce Administrative and Regulatory Burden in Cancer Clinical Trials
As reported in the Journal of Clinical Oncology, Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, Omaha, and colleagues have provided a summary of the groundwork of an initiative by ASCO and the Association of American Cancer Institutes (AACI) to identify and reduce...
